Other B7 co-inhibitory ligands, such as CD86, CD80, and HHLA2, showed high expression levels in myeloma cell lines relative to the other cancer cell lines, implying that these B7 ligands might serve as potential targets for immune checkpoint therapy. The gene discussed is HHLA2; the disease is plasma cell myeloma.